t-cell

Documents about t-cell

• Computational design of HLA class I superbinders for broad T cell immunogenicity.#156887NCBI PubMed Central
• IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma#208438ClinicalTrials.gov
• Myo1e/f regulate phagocytic podosomes to promote efficient cup closure in macrophages#241468bioRxiv / medRxiv
• Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk#252854bioRxiv / medRxiv
• Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma#252987ClinicalTrials.gov
• The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.#265350NCBI PubMed Central
• Investigate the Impact of Viscoelasticity on γδ T Cell Migratory Behaviors for Enhanced Tumor Infiltration#308142Harvard DASH
• PanKbase Integrated Single-Cell Map: A Comprehensive Atlas of Human Pancreatic Islets#349749bioRxiv / medRxiv
• Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype.#371493NCBI PubMed Central
• TCellAlign: Cross-study T-cell Populations Alignment with Nomenclature-Guided Multi-Agent Workflow#411154arXiv CS
• Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19#426776ClinicalTrials.gov
• Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma#444871ClinicalTrials.gov
• Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.#449836NCBI PubMed Central
• Human GPR174 deficiency drives polyclonal lymphoproliferative disease via defects in T cell function#456629bioRxiv / medRxiv
• E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer#471460ClinicalTrials.gov
• Tuning T-cell immunological synapse by modular DNA-Nanobody engagers for precision immunotherapy#474689bioRxiv / medRxiv
• A NOVEL CELLULAR IMMUNOTHERAPY FOR NEUROBLASTOMA#476429ScholarBank@NUS
• Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL#481773ClinicalTrials.gov
• CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy#623510ClinicalTrials.gov
• Phase Change Cells#623788DigitalCommons@USU
• Dynamics of peripheral T cell phenotype and function during tuberculosis disease progression#642710Europe PMC
• CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers.#653447NCBI PubMed Central
• RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies#804288ClinicalTrials.gov
• Modulation de l'activation des lymphocytes T CD8+ par l'enzyme IL4I1 sécrétée par les cellules dendritiques#124499HAL (France)
• CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction#261530ClinicalTrials.gov
• a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia#848310ClinicalTrials.gov
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols#201759ClinicalTrials.gov
• CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma#387144ClinicalTrials.gov
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma#387164ClinicalTrials.gov
• Precision T Cell Engineering via ZAP70 Modulation, Data-Driven Modeling, and In Vivo Delivery#651658eScholarship
• Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma#836708ClinicalTrials.gov
• Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL#845526ClinicalTrials.gov
• Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T#195320ClinicalTrials.gov
• Close Contacts Unlocked: Nanopore-Stabilized Microvilli Bypass T Cell Receptor–Ligand-Dependent T Cell Activation / Tamara Zünd, Sebastian Lickert, Willi Weber, Rafael Saxer, Marius Wenk, Janina Zünd, Tatiana Kovalchuk, Lucrezia Baldi, Nozie D. Aghaizu, Michael Daskalakis, Viola Vogel, Enrico Klotzsch#624032Deutsche Nationalbibliothek
• MAIT cells egress the thymus at several maturation stages with selective capacity to seed different tissues#153686HAL (France)
• Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?#235408IRIS
• Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)#353714Gestión del Repositorio Documental de la Universidad de Salamanca
• Leukemia cutis, a tricky diagnosis: a case report and literature review#464459IRIS
• Induction of a Th1-Type Polyfunctional T-Cell Response by the Four-segmented Rift Valley Fever Candidate Vaccine in Humans#684707Europe PMC
• CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+#162468ClinicalTrials.gov
• Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer#164904Unpaywall
• Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation#180369ClinicalTrials.gov
• HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation#268008ClinicalTrials.gov
• Spatially resolved T cell receptor tracking reveals γδT cell localization to tumor-rich regions in high-risk neuroblastoma: A Report from the Children's Oncology Group#359692bioRxiv / medRxiv
• The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer#387145ClinicalTrials.gov
• Pooling across cells to normalize single-cell RNA sequencing data with many zero counts#400295OpenAlex
• NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma#432883ClinicalTrials.gov
• Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors#623507ClinicalTrials.gov
• Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer#683078ClinicalTrials.gov
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma#830407ClinicalTrials.gov